-
China Grants Marketing Nod to Ferring Pharmaceuticals’ Rekovelle for Assisted Reproduction
•
Switzerland-based Ferring Pharmaceuticals Ltd announced that its recombinant human follicle stimulating hormone δ injection, Rekovelle, has been granted marketing approval in China. This product, a recombinant follicle stimulating hormone (rFSH) known as follitropin delta derived from human cell lines, has already received approvals across numerous countries and regions. It is…
-
WinHealth Pharma and Ferring Partner to Co-Promote Pentasa in China
•
China-based Hong Kong WinHealth Pharma Group Ltd has entered into a new partnership with Switzerland-headquartered Ferring Pharmaceuticals Ltd, this time securing co-promotion rights for Ferring’s Pentasa (mesalazine) in mainland China. This collaboration follows previous joint efforts on terlipressin and desmopressin. Partnership DetailsUnder the terms of the agreement, WinHealth Pharma will…
-
Ferring and I-Mab Expand Olamkicept Collaboration for Inflammatory Diseases
•
Swiss pharmaceutical company Ferring Pharmaceuticals has announced a strategic collaboration with China’s I-Mab Inc. (NASDAQ: IMAB) to further develop olamkicept, an interleukin-6 (IL-6) inhibitor targeting inflammatory bowel disease (IBD) and other inflammatory conditions. Originally discovered by Ferring, olamkicept was licensed to I-Mab in 2016 for development and commercialization in Asia,…
